* TRANSGENE *
1979 - Alsace
Strasbourg
www.transgene.fr/us Discovery, Immunology
Key words: Therapeutic vaccines, Immuno-therapy, Cancer, Infectious diseases
Mission: to discover and develop gene-based therapeutic vaccines and immunotherapy products
Clients: Prescribers
communication@transgene.fr
Age: 33 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up |
Managing Dir.-CEO: Archinard (Philippe) [born 1959, Ph.D. Biochemistry, Eng. Chemistry, ex-Innogenetics (CEO), Biomérieux]
Sc.Dir.-CSO: Bonnefoy (Jean-Yves) [Ph.D. immunology, ex-Pierre Fabre, Glaxo Wellcome]
Fin.Dir.-CFO: Poncet (Philippe) [HEC, ex-Aventis CropScience, Rhône Poulenc]
BusDev: Valencony (François) [HEC, ex-Mérieux, Schneider Electric]
Financers (Hist.): Mérieux (53%), Institutional investors, AFM, Public | Turnover (M€) : 5.6 (2009), 6.5 (2008), 3.2 (2006)
Total funding (M€) : 350
Last funding (M€) : 100.1
Focus : Vaccines
Position : Clinical
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .05 | Partnering development agreement with Innate Pharma for immunomonitoring services, with set-up of new company named Platine Pharma Services | R&D | [32 years] |
| 2011 .03 | Clinical trial (phase II) for TG4040 in chronic hepatitis C (recruitment completed, 154 patients) | CLIN | [32 years] |
| 2011 .01 | Partnering development agreement with Beckman Coulter for a companion diagnostic test for TG4010 | R&D | [32 years] |
| 2010 .09 | Partnering distribution agreement (also co-development) with Jennerex (USA) for Europe, CEI and Middle-East markets (exclusive distributor), concerning JX-594 (anticancer), along minorty share worth 3.8 M€ | MKTG | [31 years] |
| 2010 .05 | Public (and private) offering : 152 M€ millions d'euros (Institut Mérieux maintain 55.2 % of shares, as first stakeholder) | PBO | [31 years] |
| 2010 .03 | Licensing-out (exclusive option) of TG4010, for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications, to Novartis (10 MUS$ non-refundable option fee) | LICOUT | [31 years] |
| 2009 .12 | Designation of Fast Track Status by FDA for TG4010, a targeted immunotherapy for treatment of Non-Small Cell Lung Cancer | MKTG | [30 years] |
| 2009 .05 | Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon | MKTG | [30 years] |
| 2007 .06 | Public offering : 100.1 M€ | PBO | [28 years] |
| 2007 .04 | Licensing-out of HPV vaccine lead to Roche (terminated in February 2011) | LICOUT | [28 years] |
| 2006 .07 | Public offering : 14.3 M€, through exercise of warrants | PBO | [27 years] |
| 2005 .06 | Public offering : 34.9 M€, with refocus on therapeutic vaccines | PBO | [26 years] |
| 2004 .12 | Nomination : Philippe Archinard as CEO | ORGN | [25 years] |
| 2002 .07 | Nomination : Jean-François Carmier as CEO [ex-Transgene V.P.] | ORGN | [23 years] |
| 2001 .09 | Management restructuring : 30 heads employee reduction from 195 headcounts | ORGR | [22 years] |
| 2001 .05 | Public offering : 63.0 M€ in depositary shares for Biomérieux-Pierre Fabre and AFM (French Muscular Dystrophy Association), with refocus on cancer treatments | PBO | [22 years] |
| 2000 .11 | Nomination : Gilles Bélanger [ex-Biomérieux], as CEO | ORGN | [21 years] |
| 1998 .03 | Listing on Paris Nouveau Marché and New York Nasdaq : 100 MUS$ (about 80 M€) | PBO | [19 years] |
| 1995 .00 | Production : GMP manufacturing facility completed | INDUS | [15 years] |
| 1992 .00 | Nomination : Bernard Gilly as CEO, with refocus on gene transfer technology | ORGN | [12 years] |
| 1979 .00 | Company founded by Pierre Chambon (Ph.D., CNRS, Research Director at Pasteur Institute) and others | ORGF | [0 year] | Actualisation / Updating: 21-Sep-2011 |
|
